Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Therapie des metastasierenden Mammakarzinoms

  • Chapter
Mammakarzinom

Part of the book series: Angewandte Onkologie ((AONKOLOGIE))

  • 35 Accesses

Zusammenfassung

Obwohl viele Patientinnen mit Mammakarzinom in den Stadien I oder II mit Hilfe moderner chirurgischer, strahlentherapeutischer und adjuvanter internistisch-onkologischer Methoden von ihrer Erkrankung prinzipiell geheilt werden können, entwickeln etwa 40% aller Patientinnen mit Mammakarzinom eine metastasierende Erkrankung. Angesichts der Tatsache, daß es sich beim Mammakarzinom um einen sehr häufigen Tumor handelt — derzeit tritt die Erkrankung bei etwa jeder zehnten Bürgerin der Vereinigten Staaten von Amerika auf —, ist das Problem der Behandlung des metastasierenden Mammakarzinoms von großer klinischer Relevanz. Trotz einer breiten Palette von zur Verfügung stehenden Chemo- und Hormontherapeutika ist es aber bis jetzt nicht möglich, das metastasierende Mammakarzinom zu heilen, sodaß davon ausgegangen werden muß, daß die Metastasierung bei allen Patientinnen früher oder später zum Tod führt.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Henderson IC (1984) Chemotherapy for advanced disease. In: Bonadonna G (ed) Breast cancer: diagnosis and management. Wiley, Chichester New York Brisbane Toronto Singapore, p 247

    Google Scholar 

  2. Dunphy FR, Spitzer G, Buzdar AU, et al (1990) Treatment of estrogen-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 8: 1207

    PubMed  CAS  Google Scholar 

  3. Greenspan EM (1965) Combination cytotoxic chemotherapy in advanced disseminated breast carcinoma. J Mt Sinai Hosp 33: 1

    Google Scholar 

  4. Cooper R (1969) Combination cytotoxic chemotherapy in hormone resistant breast cancer. Proc AACR 10: 15

    Google Scholar 

  5. Broder LE, Tormey DC (1974) Combination chemotherapy of carcinoma of the breast. Cancer Treat Rev 1: 183

    Article  Google Scholar 

  6. Kolaric K, Roth A (1983) Phase II clinical trial of cis-dichlorodiamine platinum (cisDDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 11: 108

    Article  PubMed  CAS  Google Scholar 

  7. Carbone PP, Davis TE (1978) Medical treatment for advanced breast cancer. Semin Oncol 4: 417

    Google Scholar 

  8. Carter SK (1974) The chemical therapy of breast cancer. Semin Oncol 1: 131

    PubMed  CAS  Google Scholar 

  9. Davidson NE, Lippman ME (1988) Treatment of metastatic breast cancer. In: Lippman ME, Lichter AS, Danforth DN (eds) Diagnosis and management of breast cancer. Saunders, Philadelphia London Toronto Montreal Sydney Tokyo, p 375

    Google Scholar 

  10. Pötzi P, Zielinski C, Kühböck J (1985) Mitoxantrone in the treatment of advanced solid tumors. In: Ishigami J (ed) Recent advances in chemotherapy. University of Tokyo Press, Tokyo

    Google Scholar 

  11. Henderson IC, Allegra JC, Woodcock T, et al (1989) Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 560

    PubMed  CAS  Google Scholar 

  12. Chlebowski RT, Irwin LE, Pugh RP, et al (1979) Survival of patients with metastatic breast cancer treated with either combination or sequential chemotherapy. Cancer Res 39: 4503

    PubMed  CAS  Google Scholar 

  13. Zielinski CC (1991) Zytostatische Chemotherapie. In: Grabner G, Geyer G (Hrsg) Innere Medizin. Maudrich, Wien (in Druck)

    Google Scholar 

  14. Canellos GP, Pocock SJ, Taylor SG III, et al (1976) Combination chemotherapy for metastatic breast carcinoma: prospective comparison of multiple drug therapy with L-phenylalanine mustard. Cancer 38: 1882

    Article  PubMed  CAS  Google Scholar 

  15. Mouridsen HT, Palshof T, Brahm M, et al (1977) Evaluation of single drug versus multiple drug chemotherapy in the treatment of advanced breast cancer. Cancer Treat Rep 61: 47

    PubMed  CAS  Google Scholar 

  16. Rubens RD, Knight RK, Hayward JL (1975) Chemotherapy of advanced breast cancer: a controlled randomized trial of cyclophosphamide versus a four-drug combination. Br J Cancer 32: 730

    Article  PubMed  CAS  Google Scholar 

  17. Carmo-Pereira J, Costa FO, Henriques E (1980) Single drug versus combination cytotoxic chemotherapy in advanced breast cancer: a randomized study. Eur J Cancer 16: 1621

    PubMed  CAS  Google Scholar 

  18. Muss HB, White DR, Cooper MR, et al (1977) Combination chemotherapy in advanced breast cancer: a randomized trial comparing a three-versus a five-drug program. Arch Intern Med 137: 1711

    Article  PubMed  CAS  Google Scholar 

  19. Brunner KW, Sonntag RW, Martz G, et al (1975) A controlled study in the use of combined drug therapy for metastatic breast cancer. Cancer 36: 1208

    Article  PubMed  CAS  Google Scholar 

  20. Kennealey GT, Boston B, Mitchell MS, et al (1978) Combination chemotherapy for advanced breast cancer. Two regimens containing adriamycin. Cancer 42: 27

    Article  Google Scholar 

  21. Trannum BL, McDonald B, Thigpen T, et al (1982) Adriamycin combinations in advanced breast cancer. Cancer 49: 835

    Article  Google Scholar 

  22. Tormey DC (1975) Adriamycin in breast cancer: an overview of studies. Cancer Chemother Rep 6: 319

    Google Scholar 

  23. Hoogstraten B, George SL, Samal B, et al (1976) Combination chemotherapy and adriamycin in patients with advanced breast cancer. Cancer 38: 13

    Article  PubMed  CAS  Google Scholar 

  24. French Epirubicin Study Group (1988) A prospective randomized phase Ill trial comparing combination chemotherapy with cyclophosphamide, 5-fluorouracil and either doxorubicin or epirubicin. J Clin Oncol 4: 679

    Google Scholar 

  25. Italian multicenter breast study with epirubicin (1988) Phase III randomized study of 5-fluorouracil, epirubicin and cyclophosphamide versus 5-fluorouracil, doxorubicin and cyclophosphamide in advanced breast cancer: an Italian multicenter trial. J Clin Oncol 6: 972

    Google Scholar 

  26. Kührer I, Ludwig H, Scheithauer W, et al (1987) Cyclophosphamid, Mitoxantron, 5-Fluorouracil und Prednisolon als Kombinationstherapie beim metastasierten Mammakarzinom. FAC 6–9: 1415

    Google Scholar 

  27. Manni A, Pearson OH, Brodkey J, et al (1979) Transphenoidal hypophysectomy in breast cancer. Evidence for an individual role of pituary and gonadal hormones in supporting tumor growth. Cancer 44: 2330

    Article  Google Scholar 

  28. Tormey DC, Gelman R, Band PR, et al (1982) Comparison of induction chemotherapies for metastatic breast cancer. Cancer 50: 1235

    Article  PubMed  CAS  Google Scholar 

  29. Smalley RV, Carpenter J, Bartolucci A, et al (1977) A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. Cancer 40: 625

    Article  PubMed  CAS  Google Scholar 

  30. Ahmann DL, O’Fallon J, O’Connell MJ, et al (1978) Evaluation of a fixed alternating treatment in patients with advanced breast cancer. Cancer Clin Trials 5: 219

    Google Scholar 

  31. Brambilla C, DeLena M, Rossi A, et al (1976) Response and survival in advanced breast cancer after two non-cross-resistant combinations. Br Med J 1: 801

    Article  PubMed  CAS  Google Scholar 

  32. Eagan RT, Ahmann DL, Edmonson JH, et al (1975) Controlled evaluation of the combination of adriamycin (NSC-123127), vincristine (NSC-67574), and methotrexate (NSC-740) in patients with disseminated breast cancer. Cancer Chemother Rep 6: 339

    Google Scholar 

  33. Irwin LE, Chlebowski RT, Weiner JM, et al (1980) Randomized comparison of two combination chemotherapy regimens containing doxorubicin in patients with metastatic breast cancer: a Western Cancer Study Group trial. Cancer Treat Rep 64: 981

    PubMed  CAS  Google Scholar 

  34. Nemoto T, Horton J, Simon R, et al (1982) Comparison of four combination chemotherapy programs in metastatic breast cancer: comparison of multiple drug therapy with cytoxan, 5-FU, and prednisone versus cytoxan and adriamycin, versus cytoxan, 5-FU and adriamycin, versus cytoxan, 5-FU and prednisone alternating with cytoxan and adriamycin. Cancer 49: 1988

    Article  PubMed  CAS  Google Scholar 

  35. Rainey JM, Jones SE, Salmon SE (1979) Combination chemotherapy for advanced breast cancer utilizing vincristine, adriamycin, and cyclophosphamide. Cancer 43: 66

    Article  PubMed  CAS  Google Scholar 

  36. Tranum B, Hoogstraten B, Kennedy A, et al (1978) Adriamycin in combination for metastatic breast cancer. Cancer 41: 2078

    Article  PubMed  CAS  Google Scholar 

  37. Aisner J, Weinberg V, Perloff M, et al (1987) Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each ± MER) for metastatic carcinoma of the breast: a CALGB study. J Clin Oncol 5: 1523

    PubMed  CAS  Google Scholar 

  38. Bull JM, Tormey DC, Li SH, et al (1978) A randomized trial of adriamycin versus methotrexate in combination drug therapy. Cancer 41: 1649

    Article  PubMed  CAS  Google Scholar 

  39. Muss HB, White DR, Richards F, et al (1978) Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer. Cancer 42: 2141

    Article  PubMed  CAS  Google Scholar 

  40. Smalley RV, Lefante J, Bartolucci A, et al (1983) A comparison of cyclophosphamide, adriamycin and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone (CMFVP) in patients with advanced breast cancer. Breast Cancer Res Treat 3: 209

    Article  Google Scholar 

  41. Cunnings FJ, Gelmans R, Horton J (1985) Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors. J Clin Oncol 3: 932

    Google Scholar 

  42. Tormey DC, Weinberg VE, Leone LA, et al,(1984) A comparison of intermittent vs continuous and adriamycin vs methotrexate 5-drug chemotherapy for advanced breast cancer. Am J Clin Oncol 7: 231

    Article  Google Scholar 

  43. Smalley RV, Carpenter J, Bartolucci A, et al (1977) A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and CTX-MTX-5FU-VCR-P (CMFVP) in patients with metastatic breast cancer. Cancer 40: 625

    Article  Google Scholar 

  44. Tormey DC, Lippman ME, Edwards BK, et al (1978) Evaluation of intermittent vs continuous and of adriamycin vs methotrexate 5-drug chemotherapy regimens for breast cancer. Proc AACR-ASCO 19: abstract #54

    Google Scholar 

  45. Hryniuk W, Bush H (1987) The importance of dose intensity in chemotherapy of metastatic breast cancer. Semin Oncol 4: 3

    Google Scholar 

  46. Bonadonna G, Valagussa P (1987) Dose response effect of CMF in breast cancer. Semin Oncol 1: 34

    Google Scholar 

  47. Hortobagyi G, Bodey G, Rodriguez V, et al (1987) Evaluation of high dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. J Clin Oncol 3: 354

    Google Scholar 

  48. Jones R, Holland J, Strashun A, et al (1987) A phase I-II study of intensive-dose adriamycin for advanced breast cancer. J Clin Oncol 2: 172

    Google Scholar 

  49. Williams SF, Mick R, Desser R, et al (1989) High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer. J Clin Oncol 7: 1824

    PubMed  CAS  Google Scholar 

  50. Wallerstein R, Spitzer G, Dunphy F, et al (1990) A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer. J Clin Oncol 8: 1782

    PubMed  Google Scholar 

  51. Smalley RV, Murphy S, Huguley CM Jr, et al (1976) Combination versus sequential five-drug chemotherapy in metastatic carcinoma of the breast. Cancer Res 36: 3911

    PubMed  CAS  Google Scholar 

  52. Coates A, Gebski V, Bishop JF, et al (1987) Improving the quality of life during chemotherapy for advanced breast cancer: a comparison of intermittent and continuous treatment strategies. N Engl J Med 317: 1490

    Article  PubMed  CAS  Google Scholar 

  53. Plotkin D, Waugh WJ (1983) Discontinuous chemotherapy for advanced breast cancer. Am J Clin Oncol 6: 375

    Article  PubMed  CAS  Google Scholar 

  54. Hall TC, Dederick MM, Nevinney HB, et al (1963) Prognostic value of response of patients with breast cancer to therapeutic castration. Cancer Chemother Rep 31: 47

    PubMed  CAS  Google Scholar 

  55. Lewison EF (1965) Castration in the treatment of advanced breast cancer. Cancer 18: 1558

    Article  PubMed  CAS  Google Scholar 

  56. Stoll BA (1972) Castration and estrogen therapy. In: Stoll BA (ed) Endocrine therapy in malignant disease. Saunders, Philadelphia London Toronto Montreal Sydney Tokyo, p 117

    Google Scholar 

  57. Manni A, Santen R, Harvey H, et al (1986) Treatment of breast cancer with gonadotropin-releasing hormone. Endocrinol Rev 7: 89

    Article  CAS  Google Scholar 

  58. Moore FD, Van Devanter SB, Boyden CM, et al (1974) Adrenalectomy with chemotherapy in the treatment of advanced breast cancer. Objective and subjective response rates: duration and quality of life. Surgery 76: 376

    PubMed  CAS  Google Scholar 

  59. Silverstein MJ, Byron RL, Yonemoto RH, et al (1975) Bilateral adrenalectomy for advanced breast cancer: a 21 year experience. Surgery 77: 825

    PubMed  CAS  Google Scholar 

  60. Schmidt M, Nemoto T, Dao T, et al (1971) Prognostic factors affecting adrenalectomy in patients with metastatic cancer of the breast. Cancer 27: 1106

    Article  PubMed  CAS  Google Scholar 

  61. Kaufmann M, Schmid H, Kiesel L, et al (1988) GnRH-Agonisten (Zoladex)-Therapie bei prämenopausalen Frauen mit metastasierendem Mammakarzinom. Geburtshilfe Frauenheilkd 48: 528

    Article  Google Scholar 

  62. Williams MR, Walker KJ, Turkes A, et al (1986) The use of a LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer 53: 692

    Google Scholar 

  63. Kaufmann M, Jonat W, Kleeberg U, et al (1989) Goserelin, a depot gonadotropinreleasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. J Clin Oncol 7: 1113

    PubMed  CAS  Google Scholar 

  64. Preis P, Langer M, Kubista E, et al (1988) Decapeptyl als therapeutische Alternative beim metastasierenden Mammakarzinom prämenopausaler Patientinnen. Acta Med Austriaca 15: 78

    Google Scholar 

  65. Harper MJK, Walpole AL (1967) A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J Reprod Fertil 13: 101

    Article  PubMed  CAS  Google Scholar 

  66. Jordan VC (1976) Antiestrogenic and antitumor properties of tamoxifen in laboratory animals. Cancer Treat Rep 60: 1409

    PubMed  CAS  Google Scholar 

  67. Jordan VC (1988) Chemosuppression of breast cancer with tamoxifen — laboratory evidence and future clinical investigation. Cancer Invest 6: 589

    Article  PubMed  CAS  Google Scholar 

  68. Jordan VC (1986) Estrogen/antiestrogen action and breast cancer therapy. Madison, University of Wisconsin

    Google Scholar 

  69. Jordan VC (1984) Biochemical pharmacology of antiestrogenic action. Pharmacol Rev 36: 245

    PubMed  CAS  Google Scholar 

  70. Furr BJA, Jordan VC (1984) The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25: 127

    Article  PubMed  CAS  Google Scholar 

  71. Osborne CK, Boldt DH, Clark GM, et al (1983) Effects of tamoxifen in human breast cancer cell kinetics: accumulation of cells in early GI phase. Cancer Res 43: 3583

    PubMed  CAS  Google Scholar 

  72. Sutherland RN, Green MD, Hall RE, et al (1983) Tamoxifen induces accumulation of MCF-7 human mammary carcinoma cells in the GO/G1 phase of the cell cycle. Eur J Cancer Clin Oncol 19: 615

    Article  PubMed  CAS  Google Scholar 

  73. Bénry J, Green BJ, Matheson DS (1987) Modulation of natural killer cell activity by tamoxifen in stage I postmenopausal breast cancer. Eur J Cancer Clin Oncol 23: 517

    Article  Google Scholar 

  74. Patterson JS, Battersby LA, Edwards DG (1982) Review of the clinical pharmacology and international experience with tamoxifen in advanced breast cancer. Rev Endocr Rel Cancer [Suppl 9]: 563

    Google Scholar 

  75. Legha S, Muggia FM (1976) Antiestrogens in the treatment of cancer. Ann Intern Med 84: 751

    PubMed  CAS  Google Scholar 

  76. Mouridsen H, Palshof T, Patterson J (1978) Tamoxifen in advanced breast cancer. Cancer Treat Rep 62: 131

    Article  Google Scholar 

  77. Heel RC, Brogden RN, Speight TM, et al (1978) Tamoxifen: a review of its pharmacological properties and therapeutic use in the treatment of breast cancer. Drugs 16: 1

    Article  PubMed  CAS  Google Scholar 

  78. Pearson OH, Manni A, Arafah BM (1982) Antiestrogen treatment of breast cancer: an overview. Cancer Res 42: 3424

    Google Scholar 

  79. Pritchard KI, Thomson DB, Myers RE, et al (1980) Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat Rep 64: 787

    PubMed  CAS  Google Scholar 

  80. Pritchard I, Meakin JW, Sawka C, et al (1985) The role and mechanism of action of tamoxifen in premenopausal women with metastatic carcinoma of the breast. Proc ASCO 4: 54 (abstract # C-206)

    Google Scholar 

  81. Hoogstraten B, Fletcher WS, Gad-el-Mawla N, et al (1982) Tamoxifen and oophorectomy in the treatment of recurrent breast cancer. Cancer Res 42: 4788

    PubMed  CAS  Google Scholar 

  82. Planting A, Wijst JM, Alexieva-Figuseh J (1983) Tamoxifen therapy in premenopausal women with metastatic breast cancer. Proc 3rd EORTC Breast Cancer Conference 9: 17 (abstract)

    Google Scholar 

  83. Tormey DC, Lippman ME, Edwards BK (1983) Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Ann Intern Med 98: 139

    PubMed  CAS  Google Scholar 

  84. Asbury RF, Bakemeier RF, Folsch E, et al (1981) Treatment of metastatic breast cancer with aminoglutethimide. Cancer 47: 1954

    Article  PubMed  CAS  Google Scholar 

  85. Griffiths CT, Hall TC, Saba Z, et al (1973) Preliminary trial of aminoglutethimide in breast cancer. Cancer 32: 31

    Article  PubMed  CAS  Google Scholar 

  86. Smith IE, Fitzharris BM, McKinna JA, et al (1978) Aminoglutethimide in treatment of metastatic breast carcinoma. Lancet 11: 646

    Article  Google Scholar 

  87. Wells SA Jr, Santen RJ, Lipton A, et al (1978) Medical adrenalectomy with aminoglutethimide: clinical studies in postmenopausal patients with metastatic breast carcinoma. Ann Surg 187: 475

    Article  PubMed  Google Scholar 

  88. Kühböck J, Ludwig H, Pötzi P, et al (1985) Aminoglutethimidtherapie beim fortgeschrittenen Mammakarzinom. Wien Med Wochenschr: 608

    Google Scholar 

  89. Brodie AMH, Garrett WM, Hendrickson JR, et al (1983) Aromatase inhibitors, their pharmacology and application. J Steroid Biochem 19: 53

    Article  PubMed  CAS  Google Scholar 

  90. Coombes RC, Dowsett M, Goss P, et al (1984) 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet i:1237

    Google Scholar 

  91. Coombes RC, Goss PE, Dowsett M, et al (1987) 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Tumor Diagnostik & Therapie 8: 271

    Google Scholar 

  92. Dowsett M, Goss PE, Powles TJ, et al (1987) Use of the aromatase inhibitor 4hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res 47: 1957

    PubMed  CAS  Google Scholar 

  93. Goss PE, Powles TJ, Dowsett M, et al (1986) Treatment of advanced premenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report. Cancer Res 46: 4823

    PubMed  CAS  Google Scholar 

  94. Höffken K, Jonat W, Possinger K, et al (1990) Aromatase inhibition with 4hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study. J Clin Oncol 8: 875

    PubMed  Google Scholar 

  95. Bojar H (1983) Die Entwicklung der Rezeptorforschung, insbesondere in bezug auf die hochdosierte MAP-Therapie. In: Nagel GA, Robustelli del la Cuna G, Lanius P (Hrsg) Deutsch-Italienisches Onkologisches Symposium (MAP). Kehrer, Freiburg, S 23

    Google Scholar 

  96. Lang I, Zielinski CC, Tempi H, et al (1990) Medroxyprogesterone acetate lowers plasma corticotropin and cortisol but does not suppress anterior pituitary responsiveness to human corticotropin releasing factor. Cancer 66: 1949

    Article  PubMed  CAS  Google Scholar 

  97. Cavalli F, Goldhirsch A, Jungi F, et al (1983) Eine randomisierte Studie zum Vergleich einer niedrigdosierten gegenüber einer hochdosierten Medroxyprogesteronazetat-Therapie bei der Behandlung von postmenopausalen Patientinnen mit fortgeschrittenem Mammakarzinom. In: Nagel GA, Robustelli della Cuna G, Lanius P (Hrsg) Deutsch-Italienisches Onkologisches Symposium (MAP). Kehrer, Freiburg, S 147

    Google Scholar 

  98. Bumma C (1983) Metastasierendes Mammakarzinom auf Medroxyprogesteronazetat (MAP) und Hormonrezeptoren. In: Nagel GA, Robustelli della Cuna G, Lanius P (Hrsg) Deutsch-Italienisches Onkologisches Symposium (MAP). Kehrer, Freiburg, S 97

    Google Scholar 

  99. Mattson W (1983) Die Behandlung des fortgeschrittenen Mammakarzinoms mit hochdosiertem Medroxyprogesteronazetat (HD-MAP). In: Nagel GA, Robustelli della Cuna G, Lanius P (Hrsg) Deutsch-Italienisches Onkologisches Symposium (MAP). Kehrer, Freiburg, S 139

    Google Scholar 

  100. Pannuti F, Martoni A, Lenaz C, et al (1978) A possible new approach to the treatment of metastatic breast cancer: massive doses of medroxyprogesterone acetate. Cancer Treat Rep 62: 499

    PubMed  CAS  Google Scholar 

  101. Robustelli della Cuna G, Caiciati A, Bernardo Strada MR, et al (1978) High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a dose response evaluation. Tumori 64: 143

    Google Scholar 

  102. De Lena M, Brambilla C, Valagussa P, et al (1979) High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapy. Cancer Chemother Pharmacol 2: 175

    Article  PubMed  Google Scholar 

  103. Ahmann DL, O’Connell MJ, Hahn RG, et al (1977) An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy. N Engl J Med 297: 356

    Article  PubMed  CAS  Google Scholar 

  104. Cavalli F, Beer M, Martz G, et al (1983) Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: report of the Swiss Group for Clinical Cancer Research. Br Med J 2: 865

    Google Scholar 

  105. Falkson G, Falkson HC, Glidewell O, et al (1979) Improved remission rates and remission duration in young women with metastatic breast cancer following combined oophorectomy and chemotherapy. Cancer 43: 2215

    Article  PubMed  CAS  Google Scholar 

  106. Lloyd RE, Jones SE, Salmon SE (1979) Comparative trial of low-dose adriamycin plus cyclophosphamide with or without additive hormonal therapy in advanced breast cancer. Cancer 43: 60

    Article  PubMed  CAS  Google Scholar 

  107. Ahmann DL, Green SJ, Bisel HF, et al (1982) An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy: a later analysis. Am J Clin Oncol 5: 355

    Article  PubMed  CAS  Google Scholar 

  108. Cocconi G, DelLisi V, Boni C, et al (1983) Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. Cancer 51: 581

    Article  PubMed  CAS  Google Scholar 

  109. Brunner KW, Sonntag RW, Alberto P, et al (1977) Combined chemo-and hormonal therapy in advanced breast cancer. Cancer 39: 2923

    Article  PubMed  CAS  Google Scholar 

  110. Rubens RD, Begent RHJ, Knight RK, et al (1978) Combined cytotoxic and progestagen therapy for advanced breast cancer. Cancer 42: 1680

    Article  PubMed  CAS  Google Scholar 

  111. Mouridsen HT, Palshof T, Engelsman E, et al (1980) CMF versus CMF plus tamoxifen in advanced breast cancer in postmenopausal women. An EORTC trial. Eur J Cancer 1 [Stipp!’: 119

    PubMed  Google Scholar 

  112. Mouridsen HT, Rose C, Engelsman E, et al (1985) Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized EORTC Breast Cancer Cooperative Group study of CMF versus CMF plus tamoxifen. Eur J Cancer Clin Oncol 21: 291

    Article  PubMed  CAS  Google Scholar 

  113. Lippman ME, Cassidy J, Wesley M, et al (1984) A randomized attempt to increase the efficacy of cytotoxic chemotherapy in metastatic breast cancer by hormonal synchronization. J Clin Oncol 2: 28

    PubMed  CAS  Google Scholar 

  114. Allegra JC, Woodcock TM, Richman SP, et al (1982) A phase II trial of tamoxifen, premarin, methotrexate, and 5-fluorouracil in metastatic breast cancer. Breast Cancer Treat Rep 2: 93

    Article  CAS  Google Scholar 

  115. Bowman D (1983) A phase II evaluation of sequential tamoxifen, premarin, methotrexate, and 5-fluorouracil in refractory stage IV breast cancer. Proc ASCO 2: 106 (abstract)

    Google Scholar 

  116. Kührer I, Gisslinger H, Scheithauer W, et al (1990) Conventional versus cytokinetic polychemotherapy in patients with advanced breast cancer: a randomized phase Ill study. Blut 61: 336 (abstract # A 55)

    Google Scholar 

  117. Nash CH, Jones SE, Moon TE, et al (1980) Prediction of outcome in metastatic breast cancer treated with adriamycin combination chemotherapy. Cancer 46: 2380

    Article  PubMed  Google Scholar 

  118. Mohla S, Sampson CC, Khan T, et al (1982) Estrogen and progesterone receptors in breast cancer in black Americans. Cancer 50: 552

    Article  PubMed  CAS  Google Scholar 

  119. Swenerton KD, Legha SS, Smith T, et al. (1979) Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 39: 1552

    PubMed  CAS  Google Scholar 

  120. Decker DA, Ahmann DL, Bisel HF, et al (1979) Complete responders to chemotherapy in metastatic breast cancer. Characterization and analysis. JAMA 242: 2075

    Article  PubMed  CAS  Google Scholar 

  121. Valagussa P, Brambilla C, Bonadonna G (1979) Advanced breast cancer. Are the traditional stratification parameters still of value when patients are treated with combination chemotherapy? Eur J Cancer 15: 565

    PubMed  CAS  Google Scholar 

  122. Bull JM, Tormey DC, Li SH, et al (1978) A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 41: 1649

    Article  PubMed  CAS  Google Scholar 

  123. George SL, Hoogstraten B (1978) Prognostic factors in the initial response to therapy by patients with advanced breast cancer. J Natl Cancer Inst 60: 731

    PubMed  CAS  Google Scholar 

  124. Corle DK, Sears ME, Olson KB (1984) The relationship of quantitative estrogen receptor level and clinical response to cytotoxic chemotherapy in advanced breast cancer: an extramural analysis. Cancer 54: 1554

    Article  PubMed  CAS  Google Scholar 

  125. Mörz R, Francesconi M, Schemper M, et al (1982) The value of prognostic parameters for the stratification of advanced breast cancer patients. J Cancer Res Clin Oncol 102: 289

    Article  PubMed  Google Scholar 

  126. Tormey DC, Falkson G, Simon RM, et al (1979) A randomized comparison of two sequentially administered combination regimens to a single regimen in metastatic breast cancer. Cancer Clin Trials 2: 247

    Google Scholar 

  127. DeWys WD, Begg C, Band P, et al (1981) The impact of malnutrition on treatment results in breast cancer. Cancer Treat Rep 65: 87

    PubMed  Google Scholar 

  128. Derogatis LR, Abeloff MD, Melisaratos N (1979) Psychological coping mechanisms and survival time in metastatic breast cancer. JAMA 242: 1504

    Article  PubMed  CAS  Google Scholar 

  129. Cassileth BR, Lusk EJ, Miller DS, et al (1985) Psychosocial correlates of survival in advanced malignant disease? N Engl J Med 312: 1551

    Article  PubMed  CAS  Google Scholar 

  130. Coburn J, Ahmann FR, Moon T, et al (1983) The effect of prior adjuvant chemotherapy on survival in metastatic breast cancer. Breast Cancer Res Treat 3: 303

    Article  Google Scholar 

  131. Valagussa P, Rossi A, Tancini G, et al (1985) Is there any effective salvage treatment for relapsing operable breast cancer with N+? Proc ASCO 4: 56 (abstract # C-215)

    Google Scholar 

  132. Bitran JD, Desser RK, Shapiro CM, et al (1983) Response to secondary therapy in patients with adenocarcinoma of the breast previously treated with adjuvant chemotherapy. Cancer 51: 381

    Article  PubMed  CAS  Google Scholar 

  133. Buzdar AU, Legha SS, Hortobagyi GN, et al (1981) Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens. Cancer 47: 2798

    Article  PubMed  CAS  Google Scholar 

  134. Preda F, Oriana S, Perozziello F, et al (1982) Clinical response to chemotherapy and hormone therapy as first treatment after therapeutic ovariectomy in advanced breast cancer patients. Tumori 68: 1982

    Google Scholar 

  135. Oberfield RA, Cady B, Pazianos AG, et al (1979) Adrenalectomy-oophorectomy and combined chemotherapy for carcinoma of the breast with metastases. Surg Gynecol Obstet 148: 881

    PubMed  CAS  Google Scholar 

  136. Kiang DT, Kennedy BJ (1981) Chemoendocrine therapy in advanced breast cancer. Breast Cancer Res Treat 1: 105

    Article  PubMed  CAS  Google Scholar 

  137. Manni A, Trujillo JE, Pearson OH (1980) Sequential use of endocrine therapy and chemotherapy for metastatic breast cancer: effects on survival. Cancer Treat Rep 64: 111

    PubMed  CAS  Google Scholar 

  138. Legha SS, Buzdar AU, Smith TL, et al (1980) Response to hormonal therapy as a prognostic factor for metastatic breast cancer treated with combination chemotherapy. Cancer 46: 438

    Article  PubMed  CAS  Google Scholar 

  139. Chang JC, Wegowske G (1981). Correlation of estrogen receptors and response to chemotherapy of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in advanced breast cancer. Cancer 48: 2503

    Article  PubMed  CAS  Google Scholar 

  140. Cocconi G, DeLisi V, Mori P, et al (1982) Estrogen receptors and response to chemotherapy in advanced breast cancer. Tumori 68: 67

    PubMed  CAS  Google Scholar 

  141. Jonat W, Maas H, Stolzenbach G, et al (1980) Estrogen receptor status and response to polychemotherapy in advanced breast cancer. Cancer 46: 2809

    Article  PubMed  CAS  Google Scholar 

  142. Rubens RD, Hayward JL (1980) Estrogen receptors and response to endocrine therapy and cytotoxic chemotherapy in advanced breast cancer. Cancer 46: 2922

    Article  PubMed  CAS  Google Scholar 

  143. Hilf R, Feldstein ML, Savlov ED, et al (1980) The lack of relationship between estrogen receptor status and response to chemotherapy. Cancer 46: 2797

    Article  PubMed  CAS  Google Scholar 

  144. Hilf R, Feldstein ML, Gibson SL, et al (1980) The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancer. Cancer 45: 1993

    Article  PubMed  CAS  Google Scholar 

  145. Samal BA, Brooks SC, Cummings G, et al (1980) Estrogen receptors and responsiveness of advanced breast cancer to chemotherapy. Cancer 46: 2925

    Article  PubMed  CAS  Google Scholar 

  146. Young PCM, Ehrlich CE, Einhorn LH (1980) Relationship between steroid receptors and response to endocrine therapy and cytotoxic chemotherapy in metastatic breast cancer. Cancer 46: 2961

    Article  PubMed  CAS  Google Scholar 

  147. Kiang DT, Frenning DH, Gay J, et at (1980) Estrogen receptor status and response to chemotherapy in advanced breast cancer. Cancer 46: 2814

    Article  PubMed  CAS  Google Scholar 

  148. Kiang DT, Frenning DH, Goldman Al, et at (1978) Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med 299: 1330

    Article  Google Scholar 

  149. Lippman ME, Allegra JC, Thompson EB, et al (1978) The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 298: 1223

    Article  PubMed  CAS  Google Scholar 

  150. Mortimer J, Reimer R, Greenstreet R, et at (1981) Influence of estrogen receptor status on response to combination chemotherapy for recurrent breast cancer. Cancer Treat Rep 65: 763

    PubMed  CAS  Google Scholar 

  151. Rosenbaum C, Marsland TA, Stolbach LL, et at (1980) Estrogen receptor status and response to chemotherapy in advanced breast cancer: the Tufts-Shattuck-Pondville experience. Cancer 46: 2919

    Article  Google Scholar 

  152. Samann NA, Buzdar AU, Aldinger KA, et at (1981) Estrogen receptor: a prognostic factor in breast cancer. Cancer 47: 554

    Article  Google Scholar 

  153. Bloom ND, Tobin EH, Schreibman B, et at (1980) The role of progesterone receptors in the management of advanced breast cancer. Cancer 45: 2992

    Article  PubMed  CAS  Google Scholar 

  154. Osborne C, Yochmowitz M, Knight W, et at (1980) The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46: 2884

    Article  Google Scholar 

  155. Rozenczweig M, Staquet MJ, VonHoff DD, et at (1979) Prognostic factors for the response to chemotherapy in advanced breast cancer. Cancer Clin Trials 2: 165

    Google Scholar 

  156. Fey MF, Brunner KW, Sonntag RW (1981) Prognostic factors in metastatic breast cancer. Cancer Clin Trials 4: 237

    PubMed  CAS  Google Scholar 

  157. Spiegel D, Kraemer HC, Bloom JR, et al (1989) Effect of psychological treatment on survival of patients with metastatic breast cancer. Lancet 1: 888

    Article  Google Scholar 

Download references

Authors
  1. C. Zielinski
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag/Wien

About this chapter

Cite this chapter

Zielinski, C. (1992). Therapie des metastasierenden Mammakarzinoms. In: Mammakarzinom. Angewandte Onkologie. Springer, Vienna. https://doi.org/10.1007/978-3-7091-7615-3_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-7615-3_9

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-82313-2

  • Online ISBN: 978-3-7091-7615-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation